1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Colon Cancer - Pipeline Review, H1 2016

Colon Cancer - Pipeline Review, H1 2016

  • June 2016
  • -
  • Global Markets Direct
  • -
  • 672 pages

Colon Cancer - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Colon Cancer - Pipeline Review, H1 2016’, provides an overview of the Colon Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colon Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colon Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Colon Cancer
- The report reviews pipeline therapeutics for Colon Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Colon Cancer therapeutics and enlists all their major and minor projects
- The report assesses Colon Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Colon Cancer

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Colon Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Colon Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Colon Cancer - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
Introduction 8
Colon Cancer Overview 9
Therapeutics Development 10
Colon Cancer - Therapeutics under Development by Companies 12
Colon Cancer - Therapeutics under Investigation by Universities/Institutes 22
Colon Cancer - Pipeline Products Glance 25
Colon Cancer - Products under Development by Companies 29
Colon Cancer - Products under Investigation by Universities/Institutes 41
Colon Cancer - Companies Involved in Therapeutics Development 45
Colon Cancer - Therapeutics Assessment 165
Drug Profiles 189
Colon Cancer - Dormant Projects 614
Colon Cancer - Discontinued Products 632
Colon Cancer - Product Development Milestones 633
Appendix 644

List of Tables
Number of Products under Development for Colon Cancer, H1 2016 37
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2016 38
Number of Products under Development by Companies, H1 2016 39
Number of Products under Development by Companies, H1 2016 (Contd..1) 40
Number of Products under Development by Companies, H1 2016 (Contd..2) 41
Number of Products under Development by Companies, H1 2016 (Contd..3) 42
Number of Products under Development by Companies, H1 2016 (Contd..4) 43
Number of Products under Development by Companies, H1 2016 (Contd..5) 44
Number of Products under Development by Companies, H1 2016 (Contd..6) 45
Number of Products under Development by Companies, H1 2016 (Contd..7) 46
Number of Products under Development by Companies, H1 2016 (Contd..8) 47
Number of Products under Development by Companies, H1 2016 (Contd..9) 48
Number of Products under Investigation by Universities/Institutes, H1 2016 49
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 50
Number of Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 51
Comparative Analysis by Late Stage Development, H1 2016 52
Comparative Analysis by Clinical Stage Development, H1 2016 53
Comparative Analysis by Early Stage Development, H1 2016 54
Comparative Analysis by Unknown Stage Development, H1 2016 55
Products under Development by Companies, H1 2016 56
Products under Development by Companies, H1 2016 (Contd..1) 57
Products under Development by Companies, H1 2016 (Contd..2) 58
Products under Development by Companies, H1 2016 (Contd..3) 59
Products under Development by Companies, H1 2016 (Contd..4) 60
Products under Development by Companies, H1 2016 (Contd..5) 61
Products under Development by Companies, H1 2016 (Contd..6) 62
Products under Development by Companies, H1 2016 (Contd..7) 63
Products under Development by Companies, H1 2016 (Contd..8) 64
Products under Development by Companies, H1 2016 (Contd..9) 65
Products under Development by Companies, H1 2016 (Contd..10) 66
Products under Development by Companies, H1 2016 (Contd..11) 67
Products under Investigation by Universities/Institutes, H1 2016 68
Products under Investigation by Universities/Institutes, H1 2016 (Contd..1) 69
Products under Investigation by Universities/Institutes, H1 2016 (Contd..2) 70
Products under Investigation by Universities/Institutes, H1 2016 (Contd..3) 71
Colon Cancer - Pipeline by ACF Pharmaceuticals, LLC, H1 2016 72
Colon Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016 73
Colon Cancer - Pipeline by Aduro BioTech, Inc., H1 2016 74
Colon Cancer - Pipeline by Advanced Proteome Therapeutics Corporation, H1 2016 75
Colon Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 76
Colon Cancer - Pipeline by Agenus, Inc., H1 2016 77
Colon Cancer - Pipeline by AGV Discovery, SAS, H1 2016 78
Colon Cancer - Pipeline by AIMM Therapeutics B.V., H1 2016 79
Colon Cancer - Pipeline by Ambrx, Inc., H1 2016 80
Colon Cancer - Pipeline by Anavex Life Sciences Corp., H1 2016 81
Colon Cancer - Pipeline by AndroScience Corporation, H1 2016 82
Colon Cancer - Pipeline by Aphios Corporation, H1 2016 83
Colon Cancer - Pipeline by Aposense Ltd., H1 2016 84
Colon Cancer - Pipeline by Aptose Biosciences Inc., H1 2016 85
Colon Cancer - Pipeline by Asana BioSciences, LLC, H1 2016 86
Colon Cancer - Pipeline by AstraZeneca Plc, H1 2016 87
Colon Cancer - Pipeline by Aurigene Discovery Technologies Limited, H1 2016 88
Colon Cancer - Pipeline by BCN Biosciences L.L.C., H1 2016 89
Colon Cancer - Pipeline by Bio-Path Holdings, Inc., H1 2016 90
Colon Cancer - Pipeline by Biogazelle, H1 2016 91
Colon Cancer - Pipeline by Bioncotech Therapeutics S.L., H1 2016 92
Colon Cancer - Pipeline by Blirt S.A., H1 2016 93
Colon Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 94
Colon Cancer - Pipeline by Can-Fite BioPharma Ltd., H1 2016 95
Colon Cancer - Pipeline by Celprogen, Inc., H1 2016 96
Colon Cancer - Pipeline by Celyad SA, H1 2016 97
Colon Cancer - Pipeline by Chiome Bioscience, Inc., H1 2016 98
Colon Cancer - Pipeline by Critical Outcome Technologies Inc., H1 2016 99
Colon Cancer - Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2016 100
Colon Cancer - Pipeline by CytomX Therapeutics, Inc., H1 2016 101
Colon Cancer - Pipeline by Cytune Pharma SAS, H1 2016 102
Colon Cancer - Pipeline by CZ BioMed Corp, H1 2016 103
Colon Cancer - Pipeline by DEKK-TEC, Inc., H1 2016 104
Colon Cancer - Pipeline by Digna Biotech, S.L., H1 2016 105
Colon Cancer - Pipeline by Eli Lilly and Company, H1 2016 106
Colon Cancer - Pipeline by EntreChem, S.L., H1 2016 107
Colon Cancer - Pipeline by EnzymeBioSystems, H1 2016 108
Colon Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 109
Colon Cancer - Pipeline by GlycaNova Norway AS, H1 2016 110
Colon Cancer - Pipeline by Halozyme Therapeutics, Inc., H1 2016 111
Colon Cancer - Pipeline by Heat Biologics, Inc., H1 2016 112
Colon Cancer - Pipeline by Helix BioPharma Corp., H1 2016 113
Colon Cancer - Pipeline by Histogen, Inc., H1 2016 114
Colon Cancer - Pipeline by Horizon Pharma Plc, H1 2016 115
Colon Cancer - Pipeline by Huperion Sarl, H1 2016 116
Colon Cancer - Pipeline by Idera Pharmaceuticals, Inc., H1 2016 117
Colon Cancer - Pipeline by Ignyta, Inc., H1 2016 118
Colon Cancer - Pipeline by Immunome Inc., H1 2016 119
Colon Cancer - Pipeline by Immunomedics, Inc., H1 2016 120
Colon Cancer - Pipeline by Immunotope, Inc., H1 2016 121
Colon Cancer - Pipeline by Immupharma Plc, H1 2016 122
Colon Cancer - Pipeline by IMPACT Therapeutics, Inc., H1 2016 123
Colon Cancer - Pipeline by Incuron, LLC, H1 2016 124
Colon Cancer - Pipeline by Infinity Pharmaceuticals, Inc., H1 2016 125
Colon Cancer - Pipeline by Inflection Biosciences Limited, H1 2016 126
Colon Cancer - Pipeline by Innopharmax Inc., H1 2016 127
Colon Cancer - Pipeline by Intezyne, Inc, H1 2016 128
Colon Cancer - Pipeline by Ironwood Pharmaceuticals, Inc., H1 2016 129
Colon Cancer - Pipeline by Jasco Pharmaceuticals, LLC., H1 2016 130
Colon Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2016 131
Colon Cancer - Pipeline by JW Pharmaceutical Corporation, H1 2016 132
Colon Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 133
Colon Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 134
Colon Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2016 135
Colon Cancer - Pipeline by Lipocure Ltd., H1 2016 136
Colon Cancer - Pipeline by LipoMedix Pharmaceutical Inc., H1 2016 137
Colon Cancer - Pipeline by Lupin Limited, H1 2016 138
Colon Cancer - Pipeline by Lymphocyte Activation Technologies, S.A., H1 2016 139
Colon Cancer - Pipeline by MabVax Therapeutics Holdings, Inc., H1 2016 140
Colon Cancer - Pipeline by MacroGenics, Inc., H1 2016 141
Colon Cancer - Pipeline by MaxiVAX SA, H1 2016 142
Colon Cancer - Pipeline by Meabco A/S, H1 2016 143
Colon Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2016 144
Colon Cancer - Pipeline by MolMed S.p.A., H1 2016 145
Colon Cancer - Pipeline by Monopar Therapeutics LLC, H1 2016 146
Colon Cancer - Pipeline by Multimmune GmbH, H1 2016 147
Colon Cancer - Pipeline by NormOxys, Inc., H1 2016 148
Colon Cancer - Pipeline by Novartis AG, H1 2016 149
Colon Cancer - Pipeline by Omeros Corporation, H1 2016 150
Colon Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2016 151
Colon Cancer - Pipeline by OncoVista Innovative Therapies, Inc., H1 2016 152
Colon Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 153
Colon Cancer - Pipeline by Orega Biotech SAS, H1 2016 154
Colon Cancer - Pipeline by OSE Immunotherapeutics, H1 2016 155
Colon Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 156
Colon Cancer - Pipeline by PharmaCyte Biotech, Inc., H1 2016 157
Colon Cancer - Pipeline by Pharminox Limited, H1 2016 158
Colon Cancer - Pipeline by Philogen S.p.A., H1 2016 159
Colon Cancer - Pipeline by Pique Therapeutics, H1 2016 160
Colon Cancer - Pipeline by Plexxikon Inc., H1 2016 161
Colon Cancer - Pipeline by Provecs Medical GmbH, H1 2016 162
Colon Cancer - Pipeline by Provectus Biopharmaceuticals, Inc., H1 2016 163
Colon Cancer - Pipeline by Qu Biologics Inc., H1 2016 164
Colon Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H1 2016 165
Colon Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2016 166
Colon Cancer - Pipeline by Rgenix, Inc., H1 2016 167
Colon Cancer - Pipeline by Sareum Holdings Plc, H1 2016 168
Colon Cancer - Pipeline by Savoy Pharmaceuticals, Inc., H1 2016 169
Colon Cancer - Pipeline by Sellas Inc., H1 2016 170
Colon Cancer - Pipeline by Sigma-Tau S.p.A., H1 2016 171
Colon Cancer - Pipeline by Sirnaomics, Inc., H1 2016 172
Colon Cancer - Pipeline by Somantix B.V., H1 2016 173
Colon Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2016 174
Colon Cancer - Pipeline by Sphaera Pharma Pvt. Ltd., H1 2016 175
Colon Cancer - Pipeline by Starpharma Holdings Limited, H1 2016 176
Colon Cancer - Pipeline by Synergys Biotherapeutics, Inc., H1 2016 177
Colon Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 178
Colon Cancer - Pipeline by Taiwan Liposome Company, Ltd., H1 2016 179
Colon Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 180
Colon Cancer - Pipeline by Theryte Limited, H1 2016 181
Colon Cancer - Pipeline by Transgene Biotek Limited, H1 2016 182
Colon Cancer - Pipeline by TVAX Biomedical, Inc., H1 2016 183
Colon Cancer - Pipeline by Tyg Oncology Ltd., H1 2016 184
Colon Cancer - Pipeline by Vaccinogen, Inc., H1 2016 185
Colon Cancer - Pipeline by Vault Pharma Inc., H1 2016 186
Colon Cancer - Pipeline by Vaximm AG, H1 2016 187
Colon Cancer - Pipeline by VG Life Sciences, Inc., H1 2016 188
Colon Cancer - Pipeline by Yakult Honsha Co., Ltd., H1 2016 189
Colon Cancer - Pipeline by Zensun (Shanghai) Sci and Tech Co., Ltd., H1 2016 190
Colon Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2016 191
Assessment by Monotherapy Products, H1 2016 192
Assessment by Combination Products, H1 2016 193
Number of Products by Stage and Target, H1 2016 195
Number of Products by Stage and Mechanism of Action, H1 2016 205
Number of Products by Stage and Route of Administration, H1 2016 213
Number of Products by Stage and Molecule Type, H1 2016 215
Colon Cancer - Dormant Projects, H1 2016 641
Colon Cancer - Dormant Projects (Contd..1), H1 2016 642
Colon Cancer - Dormant Projects (Contd..2), H1 2016 643
Colon Cancer - Dormant Projects (Contd..3), H1 2016 644
Colon Cancer - Dormant Projects (Contd..4), H1 2016 645
Colon Cancer - Dormant Projects (Contd..5), H1 2016 646
Colon Cancer - Dormant Projects (Contd..6), H1 2016 647
Colon Cancer - Dormant Projects (Contd..7), H1 2016 648
Colon Cancer - Dormant Projects (Contd..8), H1 2016 649
Colon Cancer - Dormant Projects (Contd..9), H1 2016 650
Colon Cancer - Dormant Projects (Contd..10), H1 2016 651
Colon Cancer - Dormant Projects (Contd..11), H1 2016 652
Colon Cancer - Dormant Projects (Contd..12), H1 2016 653
Colon Cancer - Dormant Projects (Contd..13), H1 2016 654
Colon Cancer - Dormant Projects (Contd..14), H1 2016 655
Colon Cancer - Dormant Projects (Contd..15), H1 2016 656
Colon Cancer - Dormant Projects (Contd..16), H1 2016 657
Colon Cancer - Dormant Projects (Contd..17), H1 2016 658
Colon Cancer - Discontinued Products, H1 2016 659

List of Figures
Number of Products under Development for Colon Cancer, H1 2016 37
Number of Products under Development for Colon Cancer - Comparative Analysis, H1 2016 38
Number of Products under Development by Companies, H1 2016 39
Number of Products under Investigation by Universities/Institutes, H1 2016 49
Comparative Analysis by Clinical Stage Development, H1 2016 53
Comparative Analysis by Early Stage Products, H1 2016 54
Assessment by Monotherapy Products, H1 2016 192
Assessment by Combination Products, H1 2016 193
Number of Products by Top 10 Targets, H1 2016 194
Number of Products by Stage and Top 10 Targets, H1 2016 194
Number of Products by Top 10 Mechanism of Actions, H1 2016 204
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 204
Number of Products by Top 10 Routes of Administration, H1 2016 212
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 212
Number of Products by Top 10 Molecule Types, H1 2016 214
Number of Products by Stage and Top 10 Molecule Types, H1 2016 214

Companies Mentioned
ACF Pharmaceuticals, LLC
Adgero Biopharmaceuticals, Inc.
Aduro BioTech, Inc.
Advanced Proteome Therapeutics Corporation
Advenchen Laboratories, LLC
Agenus, Inc.
AGV Discovery, SAS
AIMM Therapeutics B.V.
Ambrx, Inc.
Anavex Life Sciences Corp.
AndroScience Corporation
Aphios Corporation
Aposense Ltd.
Aptose Biosciences Inc.
Asana BioSciences, LLC
AstraZeneca Plc
Aurigene Discovery Technologies Limited
BCN Biosciences L.L.C.
Bio-Path Holdings, Inc.
Biogazelle
Bioncotech Therapeutics S.L.
Blirt S.A.
Boehringer Ingelheim GmbH
Can-Fite BioPharma Ltd.
Celprogen, Inc.
Celyad SA
Chiome Bioscience, Inc.
Critical Outcome Technologies Inc.
Cyclacel Pharmaceuticals, Inc.
CytomX Therapeutics, Inc.
Cytune Pharma SAS
CZ BioMed Corp
DEKK-TEC, Inc.
Digna Biotech, S.L.
Eli Lilly and Company
EntreChem, S.L.
EnzymeBioSystems
F. Hoffmann-La Roche Ltd.
GlycaNova Norway AS
Halozyme Therapeutics, Inc.
Heat Biologics, Inc.
Helix BioPharma Corp.
Histogen, Inc.
Horizon Pharma Plc
Huperion Sarl
Idera Pharmaceuticals, Inc.
Ignyta, Inc.
Immunome Inc.
Immunomedics, Inc.
Immunotope, Inc.
Immupharma Plc
IMPACT Therapeutics, Inc.
Incuron, LLC
Infinity Pharmaceuticals, Inc.
Inflection Biosciences Limited
Innopharmax Inc.
Intezyne, Inc
Ironwood Pharmaceuticals, Inc.
Jasco Pharmaceuticals, LLC.
Jiangsu Kanion Pharmaceutical Co., Ltd.
JW Pharmaceutical Corporation
Karyopharm Therapeutics, Inc.
Kyowa Hakko Kirin Co., Ltd.
Les Laboratoires Servier SAS
Lipocure Ltd.
LipoMedix Pharmaceutical Inc.
Lupin Limited
Lymphocyte Activation Technologies, S.A.
MabVax Therapeutics Holdings, Inc.
MacroGenics, Inc.
MaxiVAX SA
Meabco A/S
Molecular Targeting Technologies, Inc.
MolMed S.p.A.
Monopar Therapeutics LLC
Multimmune GmbH
NormOxys, Inc.
Novartis AG
Omeros Corporation
Omnitura Therapeutics Inc.
OncoVista Innovative Therapies, Inc.
Ono Pharmaceutical Co., Ltd.
Orega Biotech SAS
OSE Immunotherapeutics
Panacea Pharmaceuticals, Inc.
PharmaCyte Biotech, Inc.
Pharminox Limited
Philogen S.p.A.
Pique Therapeutics
Plexxikon Inc.
Provecs Medical GmbH
Provectus Biopharmaceuticals, Inc.
Qu Biologics Inc.
Regeneron Pharmaceuticals, Inc.
Rexahn Pharmaceuticals, Inc.
Rgenix, Inc.
Sareum Holdings Plc
Savoy Pharmaceuticals, Inc.
Sellas Inc.
Sigma-Tau S.p.A.
Sirnaomics, Inc.
Somantix B.V.
Sorrento Therapeutics, Inc.
Sphaera Pharma Pvt. Ltd.
Starpharma Holdings Limited
Synergys Biotherapeutics, Inc.
Synta Pharmaceuticals Corp.
Taiwan Liposome Company, Ltd.
Takeda Pharmaceutical Company Limited
Theryte Limited
Transgene Biotek Limited
TVAX Biomedical, Inc.
Tyg Oncology Ltd.
Vaccinogen, Inc.
Vault Pharma Inc.
Vaximm AG
VG Life Sciences, Inc.
Yakult Honsha Co., Ltd.
Zensun (Shanghai) Sci and Tech Co., Ltd.
ZIOPHARM Oncology, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Hematological Cancers: Analytical Tool

Hematological Cancers: Analytical Tool

  • $ 11505
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

  • $ 6995
  • Industry report
  • September 2016
  • by GBI Research

Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation Summary Glioblastoma multiforme (GBM) is a grade IV tumor that arises from astrocytes. It is ...

Lung Cancer: Analytical Tool

Lung Cancer: Analytical Tool

  • $ 8096
  • Industry report
  • August 2016
  • by Bioseeker

Analytical Tools are cancer area specific intelligence and surveillance toolkits within a select number of hot, emerging cancer therapy areas. They are designed to empower biotech/pharma professionals ...

Ovarian Cancer: Analytical Tool

August 2016 $ 8096

Renal Cancer: Analytical Tool

August 2016 $ 8096

Bladder Cancer: Analytical Tool

August 2016 $ 8096

Brain Cancer: Analytical Tool

August 2016 $ 8096

Breast Cancer: Analytical Tool

August 2016 $ 8096

ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.